Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Apr, 2014 | Pages:
53 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Cytokinetics, Incorporated - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Cytokinetics, Incorporated - Product Pipeline Review - 2014', provides an overview of the Cytokinetics, Incorporated's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Cytokinetics, Incorporated's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Cytokinetics, Incorporated including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Cytokinetics, Incorporated's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Cytokinetics, Incorporated's pipeline products Reasons to buy - Evaluate Cytokinetics, Incorporated's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Cytokinetics, Incorporated in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Cytokinetics, Incorporated's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Cytokinetics, Incorporated and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Cytokinetics, Incorporated - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Cytokinetics, Incorporated and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Cytokinetics, Incorporated Snapshot 5 Cytokinetics, Incorporated Overview 5 Key Information 5 Key Facts 5 Cytokinetics, Incorporated - Research and Development Overview 6 Key Therapeutic Areas 6 Cytokinetics, Incorporated - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Out-Licensed Products 11 Out-Licensed Products/Combination Treatment Modalities 12 Cytokinetics, Incorporated - Pipeline Products Glance 13 Cytokinetics, Incorporated - Clinical Stage Pipeline Products 13 Phase II Products/Combination Treatment Modalities 13 Phase I Products/Combination Treatment Modalities 14 Cytokinetics, Incorporated - Early Stage Pipeline Products 15 Preclinical Products/Combination Treatment Modalities 15 Cytokinetics, Incorporated - Drug Profiles 16 tirasemtiv 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 CK-2127107 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 CK-2018488 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 CK-2018571 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 CK-2019165 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 CK-2066260 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Small Molecule To Inhibit Myosin For COPD, Asthma And Pulmonary Arterial Hypertension 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Small Molecules To Activate Myosin Light Chain Kinase For Cardiovascular Diseases 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Cytokinetics, Incorporated - Pipeline Analysis 27 Cytokinetics, Incorporated - Pipeline Products by Target 27 Cytokinetics, Incorporated - Pipeline Products by Route of Administration 28 Cytokinetics, Incorporated - Pipeline Products by Molecule Type 29 Cytokinetics, Incorporated - Pipeline Products by Mechanism of Action 30 Cytokinetics, Incorporated - Recent Pipeline Updates 31 Cytokinetics, Incorporated - Dormant Projects 39 Cytokinetics, Incorporated - Company Statement 40 Cytokinetics, Incorporated - Locations And Subsidiaries 51 Head Office 51 Appendix 52 Methodology 52 Coverage 52 Secondary Research 52 Primary Research 52 Expert Panel Validation 52 Contact Us 53 Disclaimer 53
List of Tables Cytokinetics, Incorporated, Key Information 5 Cytokinetics, Incorporated, Key Facts 5 Cytokinetics, Incorporated - Pipeline by Indication, 2014 7 Cytokinetics, Incorporated - Pipeline by Stage of Development, 2014 9 Cytokinetics, Incorporated - Monotherapy Products in Pipeline, 2014 10 Cytokinetics, Incorporated - Out-Licensed Products in Pipeline, 2014 11 Cytokinetics, Incorporated - Out-Licensed Products/ Combination Treatment Modalities, 2014 12 Cytokinetics, Incorporated - Phase II, 2014 13 Cytokinetics, Incorporated - Phase I, 2014 14 Cytokinetics, Incorporated - Preclinical, 2014 15 Cytokinetics, Incorporated - Pipeline by Target, 2014 27 Cytokinetics, Incorporated - Pipeline by Route of Administration, 2014 28 Cytokinetics, Incorporated - Pipeline by Molecule Type, 2014 29 Cytokinetics, Incorporated - Pipeline Products by Mechanism of Action, 2014 30 Cytokinetics, Incorporated - Recent Pipeline Updates, 2014 31 Cytokinetics, Incorporated - Dormant Developmental Projects,2014 39
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
